NCT01502293已完成2 期
A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma
OncoSec Medical Incorporated12 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2012年2月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 51
- 试验地点
- 12
- 主要终点
- Best Overall Objective Response Rate (ORR) by Modified "Skin" RECIST
研究概览
简要总结
This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene telseplasmid [tavo]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid [DNA] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS). ImmunoPulse IL-12® is a gene therapy approach to directly induce a pro-inflammatory response within a tumor to initiate and/or enhance anti-tumor immunity.
详细描述
Plasmid IL-12 (pIL-12) at a concentration of 0.5 mg/mL will be injected intratumorally at a dose volume of ¼ of the calculated lesion volume and a dose volume per lesion of 0.1 mL for lesions of volume < 0.4 cm3. Six pulses at field strengths of (E+) of 1500 V/cm and pulse width of 100 μs at 1-second intervals will be administered using the OncoSec Medical System (OMS) to each previously injected tumor.
Three treatment regimens will be explored:
Main Study: Treatment on Days 1, 5 and 8 for 1 cycle. Additional cycles may be repeated every 3 months at the Investigator's discretion.
Addendum Regimen A: Treatment on Days 1, 8 and 15 every 6 weeks. Subsequent cycles may be given at 6-week intervals, for up to 9 treatment cycles in total.
Addendum Regimen B: Treatment on Days 1, 5 and 8 every 6 weeks. Subsequent cycles may be given at 6-week intervals, for up to 9 treatment cycles in total.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with advanced cutaneous or subcutaneous in-transit or metastatic melanoma (main and addendum)
- •Age ≥ 18 years of age (main and addendum).
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (main and addendum).
- •Patients may have had prior chemotherapy or immunotherapy (vaccines, interferon, ipilimumab, or IL-2) with progression or persistent disease. All chemotherapy or immunotherapy (prior therapies for cancer per the addendum) must have been stopped 4 weeks prior to electroporation (main part) or prior to enrollment (addendum), unless the sponsor medical monitor approval was obtained.
- •Patients may have had radiation therapy, but must have progressive disease after radiation therapy if the lesions to be treated are within the radiation field. Per the main study Protocol Amendment 10 (Version 11.0), dated 27 April 2016, all prior treatment toxicities had to be resolved to Grade
- •Per the study Addendum Amendment 5, dated 27 April 2016, all prior chemotherapy or immunotherapy treatment-related adverse events (AEs) must have been resolved to baseline or Grade 1 at the time of study enrollment; and all prior radiation treatment AEs must have been resolved to baseline at the time of study enrollment.
- •Had a minimum of 2 eligible tumors and could have had up to 4 eligible tumors treated with electroporation (main part).
- •Must have had a lesion at baseline eligible for treatment, meeting all of the following criteria: at least 0.3 cm x 0.3 cm in longest perpendicular diameters; and accessible for electroporation (addendum).
- •Must have had at least 1 additional lesion that could have been followed for distant regression and that met all of the following criteria: must have remained untreated for duration of the study; and had longest perpendicular diameters at least 0.3 cm x 0.3 cm by clinical measurement; or at least 1.0 cm x 1.0 cm by computed tomography (CT) for non-nodal lesions; or at least 1.5 cm x 1.5 cm by CT for malignant lymph nodes (addendum).
- •For women of childbearing potential, a negative serum or urine pregnancy test within 14 days to the first study drug administration, and use of birth control from 30 days prior to the first day of study drug administration and 30 days following last day study drug administration was required. Male patients must have been surgically sterile, or must have agreed to use contraception during the study and at least 30 days following the last day of study drug administration (addendum).
- •Had a creatinine level < 2 x upper limit of normal (ULN), and serum bilirubin within institutional normal limits obtained within 4 weeks prior to enrollment (main part and addendum).
- •Had aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN within 4 weeks prior to enrollment (addendum).
- •Had an absolute neutrophil count (ANC) > 1000/mm and platelet count > 100,000 /mm within 4 weeks prior to registration (main part) or enrollment (addendum).
- •Were able to give informed consent and to follow guidelines given in the study (main part and addendum).
排除标准
- •Prior therapy with IL-12 or prior gene therapy (main and addendum).
- •Had an ECOG performance score of 3 or 4 (main part).
- •Concurrent immunotherapy, chemotherapy, or radiation therapy for duration of patient participation on study (main part and addendum). For the study addendum, approved anti PD1 agents could have been permitted at the investigator's discretion and in consultation with the sponsor's medical monitor.
- •Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry (main part) or enrollment (study addendum).
- •Pregnant or breast-feeding women (main part and addendum).
- •Women of childbearing age must have had a negative pregnancy test and had to be willing to use a highly effective method of contraception. Men who were sexually active must also have been willing to use an accepted and effective method of contraception (main part).
- •Patients with electronic pacemakers or defibrillators are excluded from this study (main part and addendum).
- •The patient is known to be positive for Human Immunodeficiency Virus (HIV) or has another confirmed or suspected immunosuppressive or immunodeficient condition (patients with thyroiditis are eligible) (addendum).
- •Life expectancy of less than 6 months (main part and addendum).
- •Had significant disease or uncontrolled disease, ie, cardiovascular renal, hepatic, endocrine, metabolic, neurologic, or other significant disease that could have limited the patient's ability to participate in the study as determined by the investigator or medical monitor (main part).
- •History of significant cardiovascular disease (i.e. New York Heart Association (NYHA) class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias) (study addendum).
- •Other clinically significant co-morbidities such as uncontrolled pulmonary disease, uncontrolled diabetes, active central nervous system (CNS) disease, active infection or any other condition that could compromise the patients participation in the study according to the investigator (study addendum).
结局指标
主要结局
Best Overall Objective Response Rate (ORR) by Modified "Skin" RECIST
时间窗: Main Study: Screening and Days 90, 180, 270 and 360; Addendum: Screening and Weeks 12, 24, 36, and 48
ORR is defined as the percentage of participants with evaluable lesions that achieved a complete response (CR) or partial response (PR) as assessed by the investigator using Modified "Skin" Response Evaluation Criteria In Solid Tumors (RECIST). CR: complete disappearance of all lesions (whether measurable or not) and the absence of new lesions for at least 4 weeks duration, confirmed by additional scan and visit 4 to 6 weeks after first documentation of CR. PR: ≥30% decrease in longest dimension (LD) from baseline lesion, and no new lesions.
次要结局
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)(From first administration of study treatment up to 30 days after last dose or until initiation of new anti-cancer treatment.)
- Objective Response Rate (ORR) by Immune Related Response Criteria (irRC)(Main Study: Screening and Days 90, 180, 270 and 360; Addendum: Screening and Weeks 12, 24, 36, and 48)
- Time to First Objective Response(From start of study treatment until overall objective response (Up to 29.7 months))
- Median Overall Survival (OS)(From the start of study treatment until death, assessed up to 30 months.)
- Regression Rate of Treated and Untreated Lesions(Main Study: Screening and Days 1, 39, 90, 120, 180, 270, 360, End Of Study; Addendum: Screening and Weeks 12, 24, 36,28, End of Study)
- Duration of Objective Response(From first documented response until disease progression (Up to 29.7 months))
- Median Progression Free Survival(From start of study treatment until disease progression or death (Up to 29.7 months))
研究者
研究点 (12)
Loading locations...
相似试验
终止
2 期
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)Head and Neck Squamous Cell CarcinomaNCT02345330OncoSec Medical Incorporated4
终止
1 期
Ipilimumab and Local Radiation for Selected Solid TumorsAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Colon CancerRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent MelanomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Rectal CancerRecurrent Small Lymphocytic LymphomaRefractory Hairy Cell LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaT-cell Large Granular Lymphocyte LeukemiaTesticular LymphomaWaldenström MacroglobulinemiaAnaplastic Large Cell LymphomaNCT01769222Stanford University3
已完成
1 期
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell CancerRenal Cell CarcinomaNCT02989714University of Michigan Rogel Cancer Center13
进行中（未招募）
1 期
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeNon Small Cell Lung CancerMetastatic MelanomaMetastatic Renal Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT03474497Megan Daly, MD18
已完成
2 期
Intratumoral Application of L19IL2 in Patients With Malignant MelanomaMalignant MelanomaNCT01253096Philogen S.p.A.25